Patent details
EP2334309 Title: TH1 VACCINATION PRIMING FOR ACTIVE IMMUNOTHERAPHY
Basic Information
- Publication number:
- EP2334309
- PCT Application Number:
- US2009059177
- Type:
- European Patent Granted for LU
- Legal Status:
- Lapsed
- Application number:
- EP098184955
- PCT Publication Number:
- WO2010039924
- First applicant's nationality:
- Translation Language:
- EPO Publication Language:
- English
- English Title of Invention:
- TH1 VACCINATION PRIMING FOR ACTIVE IMMUNOTHERAPHY
- French Title of Invention:
- SENSIBILISATION ACTIVE PAR VACCINATION À CELLULES TH1 POUR UNE IMMUNOTHÉRAPIE ACTIVE
- German Title of Invention:
- TH1-ERSTIMPFUNG FÜR AKTIVE IMMUNTHERAPIE
- SPC Number:
Dates
- Filing date:
- 01/10/2009
- Grant date:
- 31/05/2017
- EP Publication Date:
- 22/06/2011
- PCT Publication Date:
- 08/04/2010
- Claims Translation Received Date:
- Translations Received Date (B1 EP Publication):
- Translations Received Date (B2 EP Publication):
- Translations Received Date (B3 EP Publication):
- Publication date:
- 31/05/2017
- EP B1 Publication Date:
- 31/05/2017
- EP B2 Publication Date:
- EP B3 Publication Date:
- Lapsed date:
- 01/10/2017
- Expiration date:
- 01/10/2029
- Renunciation date:
- Revocation date:
- Annulment date:
Owner
- From:
- 31/05/2017
- Name:
- Immunovative Therapies, Ltd.
- Address:
- POB 974, 60850 Shoham, Israel (IL)
Inventor
- Name:
- HAR-NOY, Michael
- Address:
- Israel (IL)
Priority
1
- Priority Number:
- 101692 P
- Priority Date:
- 01/10/2008
- Priority Country:
- United States (US)
2
- Priority Number:
- 570442
- Priority Date:
- 30/09/2009
- Priority Country:
- United States (US)
Classification
- IPC classification:
- A61K 39/00; A61P 37/00; C12N 5/0783;
Publication
European Patent Bulletin
- Issue number:
- 201722
- Publication date:
- 31/05/2017
- Description:
- Grant (B1)
Annual Fees
- Annual Fee Due Date:
- Annual Fee Number:
- Expected Payer:
- Last Annual Fee Payment Date:
- Last Annual Fee Paid Number:
- Payer:
| Filing date | Document type | Number of pages |
|---|---|---|
| 28/02/2018 | Outgoing Correspondence | 1 |